Venous Malformation Clinical Trial
Official title:
Treatment of Venous Malformation by Direct Puncture Repair: Ethanol Versus Polidocanol
Vascular malformations are birth defects that happen when different stages of angiogenesis shut down. 44 - 64% of all vascular malformations are venous malformations (VMs). Sclerotherapy is the first treatment line for VMs. It acts by getting rid of the vascular endothelial cells in the lesion. One of the most common and well researched sclerosing agents for VMs is polidocanol, which is a popular counterpart for concentrated ethanol.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04409145 -
First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations
|
Phase 1/Phase 2 | |
| Completed |
NCT04637997 -
Influence of Flat-knitted Compression Stockings Class I and II on Venous Malformations
|
N/A | |
| Recruiting |
NCT03767660 -
Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation
|
Phase 4 | |
| Completed |
NCT04486599 -
Electromagnetic Navigation During Ultrasound Guided Foam Sclerotherapy for Venous Malformations
|
N/A | |
| Recruiting |
NCT04861064 -
Weekly Sirolimus Therapy
|
Phase 2 | |
| Completed |
NCT04930952 -
Complications of Ethanol-amine Oleate Intralesional Sclerotherapy
|
||
| Recruiting |
NCT05563831 -
National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
|
||
| Recruiting |
NCT04258046 -
Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation
|
Phase 2 | |
| Active, not recruiting |
NCT01347294 -
Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations
|
Phase 4 | |
| Completed |
NCT04836884 -
Vascular Anomaly Pathology and Genomics Biopsy Study
|
N/A | |
| Not yet recruiting |
NCT05983159 -
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
|
Phase 2 |